Advertisement
Document › Details
Calliditas Therapeutics AB. (4/5/19). "Press Release: Elmar Schnee and Diane Parks Proposed as New Board Members of Calliditas Therapeutics". Stockholm.
Organisation | Merck KGaA | |
Group | Merck (DE) (Group) | |
Product | pharmaceutical | |
Person | Schnee, Elmar (Cardiorentis 201110– CEO before Merck Serono S.A. 200701 CEO before Merck KGaA) | |
The nomination committee of Calliditas Therapeutics AB (NASDAQ Stockholm: CALTX) (“Calliditas”) has proposed that Elmar Schnee and Diane Parks be elected as new Board members at the company’s Annual General Meeting on May 8, 2019. Mr. Schnee is proposed as Chairman of the Board.
Mr. Schnee was previously CEO of Merck Serono and was instrumental in the acquisition of Serono by Merck KGaA. He has also served as General Partner and member of the Executive Board of Merck KGaA and has held previously several senior global management positions with UCB and Sanofi.
Mr. Schnee is the chairman of the board of directors of Santhera Pharmaceutical, and member of the board of directors of Jazz Pharmaceuticals and Stallergenes Greer as well as a board director of several private healthcare companies.
Diane Parks is a senior executive with deep sales and marketing experience from the US, where she has held positions such as Head of US Commercial for Kite Pharma, VP of Sales for Amgen and Head of Global Marketing at Pharmacyclics.
“We are excited that two exceptionally experienced professionals are proposed to the Board of Calliditas. With our commercial focus on the US and our strategic intention to build an orphan focused company, we believe that their experience will significantly benefit the company and we look forward to working with them and the rest of the Board to achieve this,” said Renée Aguiar-Lucander, CEO of Calliditas.
The information was submitted for publication, through the agency of the contact person set out below, at 11:15 am CEST on April 5, 2019.
For further information, please contact:
Mikael Widell, Head of Communications
Email: mikael.widell@calliditas.com
Telephone +46 703 11 99 60
About Calliditas
Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden, focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which the company can partially or completely participate in the commercialization efforts. The company is focused on the development and commercialization of the product candidate Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy. Calliditas Therapeutics aims to take Nefecon through a global Phase 3 study to commercialization. The company is listed on Nasdaq Stockholm (ticker: CALTX). Visit www.calliditas.com for further information.
Record changed: 2023-06-05 |
Advertisement
More documents for Calliditas Therapeutics (Group)
- [1] Calliditas Therapeutics AB. (8/25/20). "Press Release: Calliditas Appoints Group General Counsel"....
- [2] Calliditas Therapeutics AB. (8/13/20). "Press Release: Calliditas Announces Agreement to Acquire Controlling Interest in Genkyotex SA"....
- [3] Genkyotex S.A.. (8/20/18). "Press Release: Genkyotex Secures an up to €7.5 Million Gross Financing to further Expand the Development of Its Lead Product". Archamps....
- [4] Genkyotex S.A.. (8/3/17). "Press Release: Genkyotex’s GKT831 Shown to Delay Tumor Growth in Multiple Preclinical Models by Targeting Cancer Associated Fibroblasts". Archamps & Geneva....
- [5] Genkyotex S.A.. (7/27/17). "Press Release: Genkyotex Provides Business Update for Q2 2017". Archamps....
- [6] Genkyotex S.A.. (4/27/17). "Press Release: Genkyotex Provides Business Update for Q1 2017. Cash & Cash Equivalents of €21.8 million as of March 31, 2017". Toulouse & Geneva....
- [7] Genticel S.A.. (2/28/17). "Press Release: Genticel becomes “Genkyotex”. Genticel’s General Meeting Approves the Strategic Combination with GenKyoTex SA [Not for Australia, Canada, Japan, New Zealand, South Africa or the United States]". Toulouse & G...
- [8] Genticel S.A.. (2/28/17). "Press Release: Genticel Announces Its 2016 Annual Results". Paris & Toulouse....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top